Catalyst Biosciences Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ...

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vascular Biogenics (VBLT) and Marinus (MRNS) with bullish

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vascular Biogenics

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Exact Sciences (EXAS) today. The company's shares closed last Monday at $37.90, close to its

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Exact Sciences ( EXAS – Research Report ) today. The company’s shares closed last Monday at $37.90, close to its 52-week low of $35.25

RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies to improve outcomes for cancer and serious autoimmune disease patients, today announced the app

In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Vericel (VCEL). The company's shares closed last Monday at $10.84,

In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Vericel ( VCEL – Research Report ). The company’s shares closed last Monday at $10.84, close to its 52-week l

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...

Half Year 2020 Ascendis Health Ltd Earnings Call

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (PTE) and Entasis Therapeutics Holdings (ETTX)

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Invitae (NVTA) yesterday and set a price target of $32.00. The company's shares closed last

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Invitae (NVTA – Research Report) yesterday and set a price target

Pressure Biosciences (OTCMKTS:PBIO) and Horiba (OTCMKTS:HRIBF) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends